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Squamous cancer of the lung (SQCC), although no longer the premier variant of non-
small cell lung cancer, continues to impose a heavy world-wide burden. Advanced SQCC
has enjoyed little of the recent progress benefiting patients with adenocarcinoma of the
lung, but that has now begun to change. This article reviews the underlying molecular
pathology of SQCC, as well as potential new targets and the corresponding novel targeted
agents; included are some of which may soon be approvable in this notoriously hard-to-treat
indication.
Keywords: squamous, epidermoid, lung cancer, systemic treatment, molecular
INTRODUCTION
Although squamous (epidermoid) lung cancer (SQCC) represents
a declining proportion of non-small cell lung cancer (NSCLC), it
still represents about 30% of all NSCLC, and as such, accounted for
6300 of the ±24,700 new cases of lung cancer in Canada thought
to have occurred in 2013 (1). There is little if any comprehen-
sive data on the histologic subtype distribution by stage, but it is
possible that SQCC is somewhat more frequent in earlier stages as
evidenced by two large Canadian series of stage III NSCLC, in both
of which SQCC was the most frequent histological subtype (2, 3).
Up to, and including the 1990s, histological subtype was not
considered to be particularly relevant in determining either the
choice of therapy, or its outcomes, in advanced NSCLC. Of course,
it had long been realized that SQCC had certain characteristic clin-
ical features, such as a much higher incidence of hypertrophic pul-
monary osteoarthropathy (including “clubbing”), non-metastatic
paraneoplastic hypercalcemia and proximally situated, cavitating
primary lesions, compared to other types of lung cancer. Further-
more, it had also been well understood that SQCC had a stronger
association with smoking than adenocarcinoma (ADC), e.g., for
current smokers (RR 16.91 vs. 4.21) (4). Unsurprisingly, SQCC is
the histological subtype most associated with emphysema (5).
All of these features, while of great interests to diagnostic physi-
cians and respirologists, may also impact directly or indirectly on
the management of advanced NSCLC by oncologists. However,
shortly after the turn of the century, it became clear that the his-
tological subtyping of lung cancer had a previously unrecognized
importance that went way beyond the fine-tuning of management,
and even beyond the important distinction between small cell
(SCLC) and NSCLC, which had, heretofore, been the major con-
tribution of pathologists. Two types of new molecularly targeted
drugs, gefitinib and bevacizumab, and one new chemotherapeutic,
pemetrexed, seemed to have dramatically different effects (either
with respect to efficacy or toxicity) according to histology, and the
increasingly powerful techniques of genetic sequencing and analy-
sis were revealing that SQCC seemed to be a different molecular
entity from other types of lung cancer. In an era in which molec-
ular diagnostics is seen increasingly as a way not only to guide the
use of existing therapies but also to select patients for clinical trial
accrual, and most critically, as a pathway for novel drug design, the
traditional “one size fits all” categorization of advanced NSCLC is
increasingly seen as obsolete.
That having been said, it is worth noting that often, definitive
biopsy material may not be available, not even for histology let
alone molecular tests, and the clinician may be forced to rely on a
scant, non-specific cytology specimen (“NSCLC-NOS”), and the
clinical features may be the only clue to the true histology. Fur-
thermore, novel immunomodulatory drugs are definitely active in
both SQCC and ADC, and for these agents, emerging molecular
biomarkers may prove to be more predictive such that histological
subtyping of NSCLC may, at least in the immunological arena,
again become irrelevant.
CONVENTIONAL PATHOLOGY
Because histological subtype now profoundly affects clinical man-
agement, and because molecular analysis should be routine, at
least in non-SQCC, every patient with advanced NSCLC should,
if at all possible, be provided with the opportunity to undergo
a professional biopsy procedure. Paradoxically, although patients
with advanced NSCLC usually have a higher disease bulk and
more potential sites for biopsy, they still may be referred in with
a sub-optimal, cytology-only fine needle aspirate (FNA) perhaps
motivated by risk-avoidance. In skilled hands, and with an ade-
quately cellular FNA, the diagnostic accuracy and value of cytology
and a small biopsy are actually comparable and even complimen-
tary (6). Importantly, both cytology and core biopsy can each
be used for immunohistochemistry (IHC) and molecular test-
ing for EGFR and KRAS, providing a cell block-sufficient sample
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is obtained. Nonetheless, most pathology departments prefer an
adequate core biopsy both for histology (including IHC) and, if
indicated, subsequent molecular testing.
It is now generally accepted that only two major types of NSCLC
exist, ADC and SQCC, with other types being relatively uncom-
mon (7). SQCC is diagnosed by the presence of keratinization and
intercellular bridges, and the absence of features typical of ADC
(intracellular mucin and gland formation). If this distinction can-
not be rendered by conventional stains, IHC is usually adequate
and highly valuable (8). Several investigations have confirmed that
cytokeratin 5/6 (CK5/6) and p63 are most useful for SQCC, with
a recent study showing for CK 5/6, a sensitivity of 94%, speci-
ficity of 97%, PVP of 97%, and PVN of 96%. These values for p63
were 93% (sensitivity), 87% (specificity), 96% (PVP), and 94%
(PVN) (9).
Additional criteria include negativity for the ADC markers of
CK7, TTF-1, and Napsin A. Although there is some variability in
these results, it should be generally noted the SQCC of the lung
are likely to be both CK 5/6 and p63 positive, and negative for
TTF-1 or CK7. Novel immune panels continue to be developed,
and which may prove superior (10).
MOLECULAR PATHOGENESIS AND TARGETED THERAPY
The effort to elucidate the molecular abnormalities in cancer is
driven not just by curiosity or technical prowess but by a deeply
embedded belief system that mutations drive malignant behavior,
and that a description of these “driver mutations” will inevitably
lead to the design of targeted drugs that are efficacious, via inhibi-
tion of the causal chain, and non-toxic, because of the specificity
of the mutation for the cancer. Although this paradigm is overly
simplistic, it has proven accurate for ADC in respect to EGFR
mutations, and translocation of ALK; in both cases, reliable mol-
ecular tests are available, which guide the selection of available
targeted drugs, which exhibit marked if temporary activity in
subgroups of ADC with these genetic alterations. Unfortunately,
EGFR and ALK rearrangements have only been described in rare
cases of pure SQCC (11–13), but not at a frequency that would
justify testing for either mutation routinely. Furthermore, at least
in the case of those rare pure SQCCs with mutated EGFR, the tar-
geted first generation tyrosine kinase inhibitors (EGFR-TKIs) seen
to be somewhat less active than in ADC with mutated EGFR (12).
Consequently, unless there is pathological evidence of a mixed
adeno-squamous pathology (in which case it is worth testing)
(14), it is not cost-beneficial to submit SQCCs (nor, probably,
“NOS – probably squamous”) cases for molecular analysis.
Likewise, KRAS mutations, which are common in (ex-) smok-
ers with ADC, are only occasionally detected in SQCC (6.4% in
the West, 1.8% in Asia) (15). KRAS in any event remains directly
undruggable, but some believe that NSCLC patients with KRAS
mutations may be less responsive to EGFR-TKIs (16). If true, this
could explain why SQCCs do relatively well on EGFR-TKIs, despite
the absence of EGRF mutations (17).
Squamous (epidermoid) lung cancer, despite the general
absence of EGFR, ALK, and KRAS mutations, is genomically
speaking, a highly aberrant malignancy (18). This is likely related
to its close association with tobacco smoke, which contains over
5000 identified compounds, of which 73 are known carcinogens
(19). These compounds form DNA adducts once metabolically
activated. Unless repaired, these DNA lesions cause permanent
mutations in the complementary strand due to bypass polymerases
“inserting the wrong base opposite the adduct” (19). As a result of
long-term exposure, thousands of mutations occur in the respira-
tory cells of smokers, some of which affect the function of growth
regulatory genes. A variety of other processes facilitate tumorige-
nesis, such as inflammatory generation of reactive oxygen species
and gene promoter methylation.
The Cancer Genome Atlas Research Network (CGARN) study
on lung SQCC revealed many varied DNA alterations (“. . . a mean
of 360 exonic mutations, 323 altered copy number segments and
165 genomic rearrangements per tumor”) (18). Importantly, copy
number aberrations do not necessarily imply point mutations
in the DNA sequence. The mean rate of exonic somatic muta-
tions was, at 8.1 mutations per megabase, higher than any other
cancer type except melanoma. TP53 mutations occurred in at
least 81% of 178 samples of SQCC; TP53 is well known as the
“guardian of the genome.” Other mutations occurred quite often
in pathways felt to be important in the mediation of the malig-
nant phenotype, e.g., oxidative stress (KEAP1, 12%, CUL3, 7%,
and NFE 2L2, 19%); squamous differentiation (SOX2, 21%; TP63,
16%; NOTCH 1 and 2, 8% and 5%, respectively; ASCL4, 3%; and
FOXP 1, 4%). mRNA expression profiling revealed overexpression
of SOX2, TP63, and P1K3CA, corresponding to the known 3q26
chromosomal amplicon. The p40 version of p63 may act as an
oncogene, expressed by 89% of tumors; RB1 and PTEN (loss-of-
function) were also frequent. Amplification or alteration of FGFR
1, 2, and 3 were seen in 7, 3, and 2%, respectively, as well as others
involved in PI3K/RTK/RAS signaling (EGFR 9%; ERB B2 4%; ERB
B3 2%; PTEN 15%; PIK3CA 16%; AKT3 16%; STK 11, 2%; TSC
1 and 2, 3% each; KRAS 3%; HRAS 3%; NF1 11%; RASA 1 4%;
BRAF, 4%).
CDKN2A, a “known tumor suppressor gene,” encodes INK
4A/p16 and ARF/p14, which control the cell cycle. This gene is
inactivated in 77% of SQCCs (by a variety of mechanisms), often
by epigenetic silencing (21%) or homozygous deletions (19%). On
the other hand, about 30% overexpress both p16 and p14; often
with mutation (see Tables 1 and 2).
These changes were seen against a background of a high
mutational load in apparently non-contributory genes.
The authors contemplated the totality of this picture in terms
of potential therapeutic targets. They felt the location of muta-
tions in key cancer genes, such as a variety of tyrosine kinases,
serine/threonine kinases, PI3K regions, proteases, and G-protein
coupled receptors, suggested potential therapeutic targets. Unfor-
tunately, however, many of the mutations were inactivations of
tumor suppressor genes, which are currently not directly drug-
gable. FGFR alterations, however, are among the most promising,
and have recently been extensively reviewed in Ref. (20).
FGFR fibroblast growth factor receptor, is a family of 4 kinase
receptors (FGFR 1–4) spanning the cell membrane and involved in
signal transduction via downstream RAS/MAPK and PI3K/AKT
pathways. In normal physiology, FGFR signaling is involved in
angiogenesis and organogenesis. In lung cancer, serum FGF levels
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Table 1 | Selected genomic alterations in SqCC.
Gene Mutation rate Normal function Consequence of alteration Comment
(a) KEAP1 12% Oxidative stress response Loss-of-function
(a) NFE2L2 19% Oxidative stress response Activation
(a) CUL3 7% Oxidative stress response Loss–of-function
(b) SOX2 Zero Squamous differentiation Activation Amplified in 21%
(b) NOTCH1 8% Squamous differentiation Mostly loss-of-function Mutually exclusive with
TP63 or SOX2 alterations
(b) TP63 (p40 isoform) 16% Squamous differentiation Activation, oncogene
(c) TP53 ≥81% Genomic integrity, apoptosis Loss-of-function Disabled in ~90% SqCC
(d) CDKN2A 15% Cell cycle control Loss-of-function Inactivated in 72% by
several mechanisms
(d) RB1 7% Cell cycle control Loss-of-function Mutually exclusive with
CDKN2A alterations
(e) NF1 11% RAS inhibitor Loss-of-function
(e) BRAF 4% Signal transduction Activation
(e) RASA1 4% RAS inhibitor Loss-of-function
(e) KRAS <1% Signal transduction Activation Very uncommon in SqCC
(f) HLA-A 3% Antigen display Loss-of-function May permit avoidance of
immune destruction
(g) PTEN 8% PI3K/Akt pathway inhibitor Loss-of-function
(g) PIK3CA 16% PI3K/Akt pathway growth and survival Activation AKT3 also activated in 16%
(h) FGFR1 Few RTK growth/survival Activation Amplified in 21%
(h) EGFR ±1% L861Q
mutation rate
RTK in growth/survival growth function Activation Amplified in 9%, rarely
mutated
(i) MLL2 20% Chromatin regulation ?
are known to be elevated. Amplification of FGFR 1 may be char-
acteristic of SQCC. The prognostic and predictive significance of
these pathway alterations remains under investigation,but the bulk
of evidence seems to suggest over-activity correlates with a poorer
outcome.
The preclinical data have been sufficiently compelling to war-
rant the design and trialing of small molecules with FGFR
inhibitory activity, including cediranib, nintedanib, pazopanib,
and ponatinib. Nintedanib (an inhibitor of VEGFR 1–3, FGFR 1–4,
PDGFR,FLT-3,and src), is most advanced,with a positive random-
ized trial (LUME – Lung 1) in second line (docetaxel± nintedanib)
(21). About 42% of the patients had SQCC; in these, the PFS HR
0.77 was significant (p= 0.02), as it was in the ADC subgroup
(HR 0.77 p= 0.0193). Disease control was superior in the SQCC
patients (49.3% vs. 35.5%, p< 0.0001). However, the effect on
overall survival (OS) (in an exploratory analysis) seemed better
in ADC than SQCC. Nintedanib appears tolerable, with GI and
liver function abnormalities being most prominent. An excess of
12.3% of the patients required a dose reduction over placebo.
LUME-Lung 3 is a first-line phase I/II trial of nintedanib with
cisplatin/gemcitabine (NCT01346540).
Ponatinib is undergoing a phase II in SQCC as monotherapy
after prior treatment, with FGFR amplification as an eligibility
requirement (NCT01761747). A randomized trial of first-line car-
boplatin/paclitaxel± cediranib was halted early for futility (22).
Cediranib, however, has much less FGFR inhibitory activity than
VEGFR blockade.
Pazopanib, another broad-spectrum kinase inhibitor whose
actions include FGFR blockade as ancillary to VFGFR inhibi-
tion (23), is in a range of trials in A-NSCLC as monotherapy
maintenance after first-line chemotherapy (NCT01208064) and
with a variety of other traditional drugs in phase II. Other FGFR
inhibitors include AZD4547 and BGJ398 and both are in phase I
and/or phase II. FP-1039 is a FGF ligand trap also in phase I.
A series from the Massachusetts General Hospital found 16%
of 226 SQCCs exhibited FGFR 1 amplifications, but these were
not associated with any particular clinical features, suggesting that
molecular testing would be required as a biomarker. Furthermore,
the amplification was focal (24).
Looking more broadly at the pathway level, the CGARN found,
in their 178 SQCC, 69% had an alteration in one of the PI3K/AKT,
RTK, or RAS pathways, when considering either mutation in the
DNA or amplification. For instance, 26% had either EGFR ampli-
fication, an activating BRAF mutation or FGFR 1 amplification,
any of which might be targetable by an inhibitory drug. As noted,
in the Canadian BR21 trial of erlotinib (an EGFR-TKI) vs. placebo,
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Table 2 | Alterations in major pathways in SqCC.
Gene Direction of
dysregulation
Incidence Normal
function
Current
targetability
EGFR ↑ 9%
ERBB2 ↑ 4% Receptor
tyrosine
kinase:
26%
ERBB3 ↑ 2% (Potentially
targetable)FGFR1 ↑ 7%
FGFR2 ↑ 3%
FGFR3 ↑ 2%

KRAS ↑ 3%
HRAS ↑ 3%
RAS/RAF:
24%
(Potentially
targetable)
NRAS ↑ <1%
RASA1 ↓ 4%
NF1 ↑ 11%

PIK3CA ↑ 16%
AKT2 ↑ 4% PI3K/AKT:
47%
(Potentially
targetable)AKT3 ↑ 16%
PTEN ↓ 15%

CDKN2A
methylation
↓ 21%
CDKN2A
mutation
↓ 18%
CDKN2A:
72%
(Not currently
targetable)CDKN2A Exon
skip.
↓ 4%
CDKN2A Hom
del
↓ 29%

the HR in favor of drug was 0.66 in SQCC with a smoking his-
tory, almost certainly due to the driver activity of wild-type EGFR
(which is quite often overexpressed at the protein level) (25).
Finally, a significant proportion of specimens contained inacti-
vating mutations in the HLA-A gene; this might convey resistance
to emerging immunomodulatory regimens. It should also be noted
that human papilloma virus, a known carcinogen in the urogenital
tract, and in upper respiratory epithelium, has been ruled out as
instrumental in lung cancer (26).
Targetable genetic alterations in SQCC were also reviewed
recently by Heist et al. from the Massachusetts General Hospital
(27), emphasizing that inactivated tumor suppressor genes (tsgs)
can only, if at all, be indirectly targeted. They focus on com-
monly mutated genes (TP53, GRM8, BAI3, ERBB4, RUNX1T1,
KEAP1, FBXW7, and KRAS) while noting no currently avail-
able agents directed at these mutations. However, they do high-
light genomic amplifications and areas of overexpression, which,
whether mutated or not, are likely implicated as “drivers,” includ-
ing SOX2 (amplified in 20% of SQCC; and a key stem cell regula-
tor; no drugs in development); PIK3CA, affecting cell survival and
proliferation (copy no. gains in >20% SQCCs, mutated in 6.5%)
for which several drugs are in development (Table 3), especially
buparlisib, which is in phase II and GDC-0032; and FGFR 1 (dis-
cussed above, and mediating growth, survival, and angiogenesis,
for which several drugs are in development e.g., AZ4547 a specific
FGFR 1–3 blocker). Although available drugs (apart from AZ4547)
Table 3 | Molecularly targeted drugs under investigation in Sqcca.
FGFR inhibitors Cediranib; nintedanib; pazopanib; ponatinib;
AZD4547; BGJ398; FP-1039
EGFR inhibitor Afatinib; necitumumab
PIK3CA Buparlisib; GDC-0032
CDK 4/6 Palbociclib
VEGF-R Ramucirumab, motesanib
PARP Veliparib
Clusterin Custirsen
aSome of these agents have multiple other mechanisms of action in addition.
inhibit more than just the FGFR system, preclinical work confirms
that pure inhibitors of FGFR 1 will inhibit growth of FGFR1 ampli-
fied tumor cell lines; IGF1R (insulin-like growth factor receptor)
is overexpressed in some SQCCs, acting via the canonical growth
and survival pathways, but promising phase II results in SQCC
lung were not replicated in two phase III trials of figitumumab (a
monoclonal antibody against IGF1R).
Other promising targets include EphA2 (overexpression
increases invasiveness, and dasatinib is an available inhibitor);
MET (amplified in about 6% of SQCCs, and mediating pro-
liferation and invasion; multiple small molecules and antibod-
ies are in development, but recently a large phase III trial of
erlotinib± onartuzumab failed, despite a prior highly promis-
ing randomized phase II in MET overexpressors (28). A plat-
inum/paclitaxel± onartuzumab randomized phase II is pending
(NCT01519804). Rilotumumab, an inhibitor of the MET ligand
HGF/SF, is also of interest. Other targets of promise include
PDGFRA (amplified in 8–10% of SQCC; sunitinib an available
inhibitor); p53/MDM2 (p53 mutations in about 65% of SQCCs,
mostly loss-of-function; alternatively, MDM2 overexpression can
inactivate p53, as in about 7% of SQCC; no drugs yet in devel-
opment); AKT(mutated in about 5% of SQCCs; several drugs in
development); DDR2 (a RTK promoting migration, proliferation,
and survival, and mutated in about 4% of SQCCs; dasatinib may
be active); LKB1 (a cell cycle regulator, inactivated in 5–20%; not
yet drugged); PTEN (a tsg, and negative regulator of PI3K/AKT,
which is then de-repressed when PTEN inactivated, very frequent
in both types of NSCLC, especially SQCC; PI3K inhibitors are
logical here); NRF2/KEAP1 (an oxidative stress response system;
KEAP1 negatively regulates NRF2,and dysregulation of either gene
is common in SQCC; no drugs in development yet).
The cyclin-dependent kinases, CDK 4 and 6 are another target
of interest and the inhibitor palbociclib (PD-0332991) is in phase
II in SQCC.
EGFR is commonly overexpressed (but rarely mutated) in
SQCC. The overexpression may be associated with amplifica-
tion or polysomy (29–31). FLEX, a first-line phase III trial
of cisplatin/vinorelbine± cetuximab, was especially positive in
both types of NSCLC if, in an explanatory analysis, EGFR
was overexpressed by IHC, independent of mutation status (32,
33), but this remains controversial. As noted, BR.21, a last-
line study of erlotinib vs. placebo, showed a beneficial HR
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0.67 for SQCC. A 545 patient, first-line phase III trial of cis-
platin/gemcitabine± necitumumab, a novel, fully human lgG1
monoclonal antibody, has just been reported as positive for OS
(median survival 11.5 vs. 9.9 months, HR 0.84, p= 0.012). One-
and 2-year survival also favored the necitumumab arm (34).
Patients <70 years seemed to fare better, but the H-score bio-
marker seemed to exhibit at most a trend for more benefit at
higher levels of EGRF expression. Another (phase II) RCT is
testing carboplatin/paclitaxel± necitumumab in first-line SQCC
(NCT0176939). Some ±5% patients with SQCC exhibit a trun-
cated form of EGFR known as EGFR-vIII, which is transform-
ing, but which lacks an extra-cellular domain, and may be less
amenable to inhibition by antibody. Lux-Lung 8 is an ongoing
phase III study of a novel, pan-HER, irreversible inhibitor afa-
tinib, vs. erlotinib, in last-line SQCC, and initial reports indicate a
modest superiority over erlotinib (35). It remains an open ques-
tion as to whether EGFR by IHC or gene copy number, can suffice
as a biomarker for benefit from anti-EGFR agents in SQCC.
The VEGF/VEGFR angiogenesis pathway is clearly implicated
in SQCC progression (36). Bevacizumab, a VEGF-sequestration
antibody, caused an unacceptable rate of fatal hemoptysis in SQCC
(37). Whether this relates to the tendency of SQCC to have cav-
itating primaries close to major airways, or some more complex
association with squamous histology, is still unresolved; however,
bevacizumab was only approved for use in non-SQCCs, for safety
reasons. Bevacizumab may well be active in SQCCs and may be
safer in patients with excised primaries; this is not known and
would be off-label.
Ramucirumab, a fully human lgG1 monoclonal antibody to
VEGRF-2, was recently the subject of a randomized phase III
trial (REVEL: docetaxel± ramucirumab) in second-line NSCLC
including SQCC. It was positive for OS; REVEL included 328
SQCC patients, who experienced a modest OS benefit (9.5
vs. 8.2 months, HR 0.88) in a subgroup analysis (38). Mote-
sanib, a small molecule VEGF-R inhibitor, seemed ineffective and
prohibitively toxic in a recent randomized trial (39).
It is noteworthy that the successful RCTs in SQCC involve
agents not directed at mutated proteins, but at normal compo-
nents of upregulated pathways in which the specificity arises from
contextual, causal dependence rather than biomolecular structural
differences. Furthermore, as is usual, the benefits, albeit welcome,
appear to be temporary. With the exception of chronic myeloid
leukemia and bcr-abl inhibitors, targeted drugs based on the mol-
ecular causality principle have uniformly provided only temporary
benefit.
RECOGNITION-BASED TARGETING
Interference in the causal chain mediating malignancy is not the
only way to target cancer; another way is based on the princi-
ple of recognition. The immune system exploits this to protect
us very effectively against foreign organisms, and also, cellular
transformation; its direct targets are surface-based biomolecular
differences (“markers”), irrespective of whether they are causally
important drivers or not. Until recently, it was quite erroneously
believed that most cancers were not “antigenic enough” to evolve
an effective immune response (IR); however, it is now appreciated
that the problem is more that the local milieu within the tumor
environment is immunosuppressive, partly because of the manip-
ulation of the immune system by negative regulators expressed
on the tumor cells, and (still under-appreciated) the highly pro-
teolytic and extremely acidotic extra-cellular milieu in tumors
(40), which is likely to damage the three-dimensional structure
of extra-cellular recognition peptides on which the IR is utterly
dependent.
Squamous (epidermoid) lung cancer cells, by virtue of the very
high mutation burden, are likely to express altered proteins as effi-
cient neoantigens in the context of HLA. (The latter, as noted, may
be mutated, potentially compromising antigen presentation in
SQCC.) New immunomodulatory agents, also known as“immune
checkpoint inhibitors,” which have proven effective in both forms
of lung cancer (as well as melanoma), derive from an understand-
ing of the “immunological synapse” (41), a complex network of
positive and negative regulatory interactions that occur among
the tumor cells, the dendritic antigen-presenting cells and the T
lymphocytes, and which strongly influence whether these effector
(cytotoxic) T-cells are activated or not.
So far, useful therapies have been developed to block CTLA4
(an early negative regulator on T-cells, active in draining lymph
nodes), with a monoclonal antibody, and the PD-L1/PD1 inter-
action (with monoclonal antibodies directed against either the
PD-1 negative regulator on the T lymphocytes, or the PD-L1 lig-
and on the tumor cell, including SQCC cells, or dendritic cell).
This system acts later in the “cancer-immunity cycle,” (42), in
the actual tumor milieu. Monoclonal antibodies against all three
targets have shown surprising activity in lung cancer, and are in
accelerated development; side effects have generally been tolera-
ble, with a range of auto-immune effects, more associated with
the anti-CTLA4 monoclonal antibody ipilimumab, and rare but
potentially serious pneumonitis with the prominent anti PD-1
agent nivolumab.
The CA184-041 study tested two regimens of combina-
tion ipilimumab with chemotherapy (concurrent or phased) vs.
chemotherapy only; the phased (but not the concurrent) PFS
was significantly superior to the chemotherapy only arm. The
SQCC patients seemed to benefit more (HR 0.48 for OS) (43).
NCT01285609, an ongoing phase III, tests the combination vs.
chemotherapy in first-line SQCC, using the apparently superior
phased regimen.
The anti-PD1 agent nivolumab achieved a 6/18 ORR (SQCC) in
a phase I study; despite heavy pre-treatment, OS at 2 years was 24%
across all 129 NSCLC patients (44). NCT01721759 is an ongoing
phase II in SQCC (third line). A phase III in SQCC (nivolumab
vs. docetaxel) is underway (NCT01642004), as are phase I tri-
als in A-NSCLC with the various platinum doublets, and also in
the highly promising combination with ipilimumab. The role of
tumor cell expression of PD-L1 as a biomarker is being investi-
gated in these studies. MK-3475 in another anti-PD1 monoclonal
antibody with a 2/6 ORR in SQCC, being moved into phase II/III
(NCT01905657), and another pending phase III (NCT0214738),
also focused on PD-L1 expressing tumors.
Several anti-PD-L1 antibodies have also shown some activ-
ity against SQCC such as BMS-936559 (45). MPDL3280A is
www.frontiersin.org December 2014 | Volume 4 | Article 320 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vincent Squamous histology
Table 4 | Checkpoint inhibitors under evaluation in advanced SqCC (selected studies).
ClinicalTrials.gove Identifier,
agent, trial name
Target Phase Line Design Status
NCT01285609 CTLA-4 III 1st Carboplatin/paclitaxel± Ipilimumab Recruiting
Ipilimumab
NCT01721759 PD-1 II 3rd Single agent nivolumab Active, not
recruitingNivolumab
Checkmate 063
NCT01642004 PD-1 III >1st Nivolumab vs. docetaxel Active, not
recruitingNivolumab
Checkmate 017
NCT02041533 PD-1 III 1st Nivolumab vs. investigator’s choice chemotherapy Recruiting
Nivolumab
Checkmate 026
NCT01454102 PD-1 I Multiple Nivolumab with various platinum doublets and/or
biologicals/targeted agents including ipilimumab,
erlotinib
Recruiting
Nivolumab
Checkmate 012
NCT01295827 PD-1 I/II ≥1st Low and high doses, q2 and 3 week schedule Active, not
recruitingPembrolizumab
KEYNOTE 001
NCT02220894 PD-1 III 1st Pembrolizumab vs. carboplatin/paclitaxel (or
pemetrexed)
Not yet open
Pembrolizumab
KEYNOTE 042
NCT02039674 PD-1 I/II ≥1st Pembrolizumab with various platinum doublets
and/or biologicals/targeted agents
Recruiting
Pembrolizumab
KEYNOTE 021
NCT02007070 PD-1 II 2nd Single agent Recruiting
Pembrolizumab PTO
KEYNOTE 025
NCT01905657 PD-1 II/III ≥2nd 2 doses of Pembrolizumab vs. docetaxel Recruiting
Pembrolizumab
KEYNOTE 010
NCT0214738 PD-1 III 1st Pembrolizumab vs. platinum doublet Not yet
recruitingPembrolizumab
KEYNOTE 024
NCT01846416 PD-L1 II ≥1st Single agent Active, not
recruitingMPDL3280A
FIR
NCT02031458 PD-L1 II ≥1st Single agent Recruiting
MPDL3280A
BIRCH
NCT01903993 PD-L1 Random II 2nd MPDL3280A vs. docetaxel Active, not
recruitingMPDL3280A
POPLAR
NCT02008227 PD-L1 III 2nd MPDL3280A vs. docetaxel Recruiting
MPDL3280A
OAK
(Continued)
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Table 4 | Continued
ClinicalTrials.gove Identifier,
agent, trial name
Target Phase Line Design Status
NCT02087423 PD-L1 II 3rd Single agent Recruiting
MEDI4736
NCT02000947 PD-L1 I ≥1st MEDI4736 with Tremelimumab Recruiting
MEDI4736
NCT02154490 PD-L1 II/III 2nd Multi-arm master protocol vs. docetaxel for various
targeted agents including MEDI4726
Recruiting
MEDI4736
LUNG-MAP
NCT02087423 PD-L1 II 3rd Single agent Recruiting
MEDI4736
ATLANTIC
Ref for this table: Clinical Trials.gov accessed 31 August 2014.
another anti-PD-L1 monoclonal with early demonstrated activ-
ity in SQCC (3/20), especially associated with IHC positivity of
PD-L1 (46). NCT01903993 will compare MPDL3280A with doc-
etaxel in 2L, followed by the phase III (NCT02008227). MEDI4736
is another anti PD-L1 agent entering phase II in advanced NSCLC
(ATLANTIC NCT02087423) and phase III in stage III (PACIFIC),
including SQCC.
Readers are referred to two excellent overviews for further
details (47, 48), and to Table 4.
BONE METASTASES
Bone metastases may occur in any type of lung cancer, and two cat-
egories of drugs have shown efficacy in reducing skeletal-related
events (SREs). The bisphosphonate zoledronic acid (49–51) is
well studied, and patients with elevated osteoclast marker (N-
telopeptide of type 1 collagen) appear to experience an OS benefit
(52). Denosumab, a monoclonal antibody against RANK-ligand,
an osteoclast activator, led to an OS benefit compared with zole-
dronic acid, in a large NSCLC subgroup analysis (51) (HR 0.78,
p= 0.01) in which the biggest benefit was experienced by SQCC
(HR 0.68 p= 0.035), and also which was associated with a lower
incidence of SREs than zoledronic acid (53).
CHEMOTHERAPY
No particular third-generation platinum doublet stands out as
clearly superior in advanced SQCC, and the decision should be
made based on toxicity avoidance (54). In a subgroup analysis
of ECOG1594, a large four-armed phase III of taxane and gemc-
itabine platinum doublets, cisplatin/gemcitabine had the best PFS
(4.3 months) and OS (9.4 months) in SQCC, but the differences
were not statistically significant. Pemetrexed, however, whether as
a single agent or in combination with cisplatin, is inferior and
contra-indicated in SQCC, despite its superiority in ADC and
large cell (55, 56). Pemetrexed is also ineffective in prolonging
either PFS of OS in maintenance in SQCC, in contrast to non-
SQCC (57). Pemetrexed may be less efficacious in SQCC because
of higher thymidylate synthase levels (58, 59), although differential
expression of the folate receptor alpha may also be important (60).
Nab-paclitaxel with carboplatin appears to be superior to pacli-
taxel/carboplatin in SQCC, with a higher ORR and less grades 3/4
neuropathy and arthralgia in SQCC (61). Neither PFS nor OS were
different. The 41% ORR for the nab-paclitaxel arm is notable, as
it was independently reviewed in Ref. (62).
In Japan, the LETS phase III study demonstrated the superi-
ority of carboplatin/S-1 over carboplatin/paclitaxel in SQCC (HR
0.713; 14.0 vs. 10.6 months) (63). S1 is an oral fluoropyridine.
Further improvements in chemotherapy are unlikely to emerge
without the addition of biologicals, some of which have been
detailed above. One additional possibility relates to PARP
inhibitors. PARP (poly ADP-ribose polymerase) is an enzyme that
participates in several DNA repair pathways (64) and is believed
to be important particularly in SQCC (65). An initial randomized
phase II experience suggested significant benefit in SQCC with
veliparib, a PARP inhibitor (PFS HR 0.50) OS HR 0.72), when
added to carboplatin/paclitaxel (66) NCT01560104, a phase III
trial of first-line platinum chemotherapy, ±veliparib (ABT-888),
is currently underway. An earlier trial of chemotherapy± iniparib
failed, probably because iniparib might not be a sufficiently active
PARP inhibitor (67).
The efficacy of chemotherapy may be also be attenuated by
anti-apoptotic (pro-survival) proteins like clusterin, expressed in
about 70% of NSCLC, apparently unrelated to histological subtype
(68, 69). A phase I/II trial of platinum/gemcitabine with clus-
terin, a 2.0 generation antisense oligonucleotide, achieved an OS
of 14.1 months, which was thought sufficient to justify the phase
III trial now underway.
CONCLUSION
The proportionate reduction in SQCC is likely to be the result of an
ongoing reduction in cigarette smoking (70); however, as long as
tobacco products (and, probably, marijuana) (71) are consumed,
this disease will be a major public health concern. Although most
of the progress in lung cancer in the last decade has occurred
in ADC, a recent spate of positive trials has, at last, brightened
the prospects for SQCC. OS gains have been shown for ramu-
cirumab, necitumumab, cetuximab, denosumab, and nintedanib
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(to be prospectively confirmed); although these results are mod-
est, they do provide a foundation upon which to explore novel
biomarkers and potentially synergistic drug combinations. Fur-
thermore, immunomodulators such as anti-PD-1/PD-L1 agents
are unquestionably active. The rapidly expanding trove of knowl-
edge on the volatile genome of SQCC has thrown up some further
target opportunities, such as the FGFR family. This progress will
likely serve to push the 1-year median OS consistently through
the 1-year barrier; beyond that, further radical innovation will be
necessary.
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